Products Overview

Human induced pluripotent stem cells (iPSCs) possess a unique ability to proliferate indefinitely and differentiate into various cell types found in the human body under certain conditions. iPSCs offer an excellent source for developing well-characterized and homogeneous cell therapy candidates that can be readily used to treat a large number of patients.

Our team leverages our expertise in iPSC biology to engineer, isolate, and select iPSCs at the GMP facility, and ultimately establish a human iPSC repository exclusively for Taiwanese. We guide the differentiation of these master iPSC lines to generate different somatic cell types, such as Mesenchymal stem cells (iMSCs), endothelial cells (iPSC-ECs), cardiomyocytes (iPSC-CMs), and NK cells (iNKs) and are actively developing a series of off-the-shelf cell therapy products from these master iPSC lines.

Endothelial Cells (ECs) are one of the essential, fundamental cells found in the human blood vessel system, and are crucial for the maintenance of healthy and functional blood vessels. These ECs usually line up and form a single layer in the interior of our blood vessels. Recent studies have revealed that ECs can play a significant role during the formation of blood vessels, predominantly through the production of relevant paracrine factors, leading to vascular regeneration and increased collateral vessel formation.

Our team is currently developing a workflow of iPSC-derived endothelial cell product candidates to treat critical limb ischemia. The establishment of this pipeline will provide higher-quality cells for the treatment of cardiovascular disease patients, while also offering more comprehensive resources for clinical and academic research related to the disease. We will continue to develop the production process and related technologies for ECs to meet future market demands and drive advancements in the field of cardiac regenerative medicine.

Cardiomyocytes are specialized cells found in the heart's muscular tissue, known as myocardium. They play a crucial role in the contraction and relaxation of the heart, enabling it to pump blood throughout the body.

Dysfunction or damage to cardiomyocytes can lead to various heart conditions, including cardiomyopathies, heart failure, and arrhythmias. Since adult cardiomyocytes have limited proliferation ability, patients suffering from cardiovascular diseases usually fail to recover by conventional treatments, while iPSCs have the potential to reproduce themselves almost indefinitely, and can be differentiated into various cell types, iPSCs have become one of the most promising starting materials for cardiac stem cells therapy.

Recent research has shown that by introducing the iPSC-CMs into impaired primates’ hearts, iPSC-CMs can be integrated into primates’ hearts, and thus improve heart function post-myocardial infarction. Our team is aiming to translate the current cardiomyocyte differentiation protocol, into the large-scale pipeline, in compliance with the PIC/S GMP regulations.

Mesenchymal stem cells (MSCs) are a group of cells with multipotent differentiation potential, capable of differentiating into various tissues and cell types and possessing tissue repair and extracellular matrix functions. In recent years, iPSCs-derived MSCs (iPSC-MSCs or iMSCs) have attracted widespread research interest. Studies have shown that iMSCs have the potential to treat conditions such as allogeneic arthritis and tissue repair.

We are committed to producing high-quality iMSCs in a laboratory that complies with PIC/S GMP certification standards. In addition to producing stable iMSCs to meet market demands, we continuously improve our production processes and technologies to ensure product quality stability, and consistency.

In the future, we will closely collaborate with medical institutions and relevant experts to conduct clinical trials and technical exchanges. Our goal is to further study the efficacy and safety of iMSCs in disease treatment, and ensure that all applications meet the highest medical standards and regulatory requirements. Through relentless efforts, we aim to expand the application of iMSCs technology into broader fields, providing more effective treatment solutions for patients.